Introduction Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed. This study explores whether an abnormal CgB paired with a normal CgA provides any useful clinical information in NET patients.
Method A prospective NET database (01/2007–11/2014) was interrogated for paired radioimmunoassay CgA (two assays; normal <6 nmol/L and 60 pmol/L) and CgB (two assays, normal <3 nmol/L, <150 pmol/L) results.
Results 1161 paired CgA and CgB results (479 patients) were retrieved. 51 patients had an isolated abnormal paired CgB (79 results; mean CgB result=2.68xULN); 2 patients were excluded as coding error. Primary sites were 24 pancreas, 9 small bowel, 4 rectal, 3 duodenal, 3 unknown, 2 duodenal-jejunal, 2 pre-sacral, 1 caecal and 1 lung. In 8/9 small bowel NETs, the CgB was raised in isolation on only one occasion on longitudinal testing. The tumour grades were 24 G1, 18 G2, 4 G3 and 3 unknown. Liver metastases were present in 38/49 patients.
Conclusion An isolated abnormal paired CgB was observed in 11% of NET patients. In 59% of patients it was associated with a pancreatic or duodenal primary NET. In 78% liver metastases were present. Further assessment is required to establish the role of CgB when paired with CgA as a biomarker of clinical utility in the diagnosis, prognosis and therapeutic monitoring of NETs.
Disclosure of interest None Declared.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.